Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in iranian population

Urology Journal

Volumn 7, Issue 2, 2010, Pages 99-104

  Amirrasouli, Houshang ^a   Kazerouni, Faranak ^a   Sanadizade, Mohammad ^b   Sanadizade, Javad ^b   Kamalian, Nasser ^c   Jalali, Mohammadtaha ^d   Rahbar, Khosro ^e   Karimi, Kamran ^b  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b Mehrad General Hospital   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benign prostate hyperplasia; Biopsy; Early detection of cancer; Prostate specific antigen; Prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; HUMAN; IRAN; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; IRAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 78649703967     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-90. 2.
2. Dalva I, Akan H, Yildiz O, Telli C, Bingol N. The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen. Int Urol Nephrol. 1999;31:675-80.
3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-16.
4. Carter HB. Prostate cancers in men with low PSA levels--must we find them? N Engl J Med. 2004;350:2292.
5. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4.
6. Lacher DA, Thompson TD, Hughes JP, Saraiya M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04. Adv Data. 20061-12.
7. Lieberman S. Can percent free prostate-specific antigen reduce the need for prostate biopsy? Eff Clin Pract. 1999;2:266-71.
8. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostatespecific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222-6.
9. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917-29.
10. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996;48:55-61.
11. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, agespecific reference ranges, and PSA density. Urology. 1995;46:779-84.
12. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Jama. 1995;274:1214-20.
13. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama. 1998;279:1542-7.
14. Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. Urology. 2003;61:760-4.
15. Leinonen J, Lovgren T, Vornanen T, Stenman UH. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem. 1993;39:2098-103.
16. Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-5.
17. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. Jama. 1993;270:948-54.
18. Gann PH, Ma J, Catalona WJ, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol. 2002;167:2427-34.
19. Parkin DM, Whelan SL, Ferlay J, Storm HH. Cancer incidence in five continents: Intl Agency for Research on Cancer; 2006.
20. Safarinejad MR. Population-based screening for prostate cancer by measuring free and total